In a new study led by Yale Cancer Center, researchers show the nucleoside transporter ENT2 may offer an unexpected path to circumventing the blood-brain barrier (BBB) and enabling targeted treatment of brain tumors with a cell-penetrating anti-DNA autoantibody.
A study led by researchers at Yale Cancer Center, Stony Brook University and KDx Diagnostics, Inc., examined a revolutionary new urine screening test that utilizes a novel Keratin 17 (K17) cancer biomarker, and revealed the test can detect the presence of new bladder cancer in patients with hematuria, or blood in the urine.
In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income. The results were published online today in the Journal of Clinical Oncology (JCO).
In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat advanced melanoma, a deadly form of skin cancer. The findings were published today in the Journal of Experimental Medicine.
Maryam Lustberg, MD, MPH, has been appointed Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. She will also join the faculty at Yale Cancer Center as an Associate Professor of Medicine (Medical Oncology).
Rachel Adams Greenup, MD, MPH, FACS, has been appointed as Associate Professor of Surgery (Oncology) and Section Chief of Breast Surgery for the Department of Surgery at Yale School of Medicine. In her new role, Dr. Greenup will provide breast surgical oncology leadership across the Smilow Cancer Hospital Network and Care Centers.
Roy S. Herbst, MD, PhD, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, has been selected as the 2020 Clinical Research Award recipient by the Association of Community Cancer Centers for significantly and positively impacting oncology patients, their families, and the broader oncology community.
In a new study by Yale Cancer Center, researchers found substantial regional variation in use of genomic testing for prostate cancer, raising questions about access and other factors that might promote rapid adoption of new cancer technologies.
The Connecticut Lions Eye Research Foundation has awarded a grant to Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center.
Michaela A. Dinan, PhD, has been appointed Co-Leader of the Cancer Prevention and Control Research Program at Yale Cancer Center.
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer, according to a new study led by Yale Cancer Center researchers.
The National Cancer Institute has awarded a UM1 grant renewal to Yale Cancer Center. The 6-year, $3 million a year grant will fund early phase investigator-initiated clinical trials to develop new potential therapies for treating both solid tumors and hematologic malignancies.
Marcella Nunez-Smith, MD, MHS, has been appointed Director of the Center for Community Engagement and Health Equity for Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH), as well as Chief Health Equity Officer & Deputy Chief Medical Officer, at SCH, and Associate Cancer Center Director for Community Outreach and Engagement at YCC.
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
There are substantial costs associated with breast cancer screenings for U.S. women in their 40s, a new Yale Cancer Center-led study finds, and these costs vary widely by region.
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).
Raymond Lenox, APRN, was presented with the Yale Cancer Center Ruth McCorkle Oncology Advanced Practice Provider Award at YCC’s annual Conclave.
Qin Yan, Ph.D., was presented with the Yale Cancer Center (YCC) Class of 1961 Cancer Research Award at YCC’s annual Conclave
Yale Cancer Center (YCC) held its annual Conclave and award ceremony. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13.
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Sarah Mougalian, M.D., assistant professor of Medicine (Medical Oncology) has been named the inaugural Deputy Chief Ambulatory Officer at Smilow Cancer Hospital (SCH) at Yale New Haven Hospital.
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer
A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.